10:54 AM EDT, 08/06/2024 (MT Newswires) -- TG Therapeutics ( TGTX ) rallied Tuesday, climbing almost 21% in morning trading, after reporting Q2 net income of $0.04 per diluted share, compared with a loss of $0.34 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.05.

Revenue for the quarter ended June 30 was $73.5 million, compared with $16.1 million a year earlier.

Analysts expected $65.9 million.

For 2024, the drug maker increased its revenue projection for its Briumvi multiple sclerosis medication to a new range of $290 million to $300 million, compared with $270 million to $290 million previously.

Price: 20.75, Change: +3.54, Percent Change: +20.57